Celgene at a conference yesterday noted that the Endoscopy data from the GED-301 trial may be available later this year, versus previously hinting the data would be available in the first half of 2017, Citi analyst Robyn Karnauskas tells investors in a research note. GED-301 will likely become a very important part of Crohn's management should the data provide evidence of mucosal healing, Karnauskas contends. She sees $6-$12 of share upside on positive data and a similar downside range on negative data. The analyst has a Buy rating on Celgene with a $127 price target.